Navigation Links
New Expert Report Dispels Common Myths About Aspartame
Date:9/11/2007

rsity; Ron Walker of the University of Surrey, United Kingdom; and Gary Murray Williams of New York Medical College. Their specialties, in addition to pharmacology and toxicology, include microbiology, biostatistics, and risk assessment.

To access the abstract, the evaluation summary and the conclusions of the panel's report, please visit http://www.aboutaspartame.com.

The Aspartame Resource Center is supported by Ajinomoto Food Ingredients LLC, a leading global manufacturer of aspartame, as a service to health professionals and consumers.


'/>"/>
SOURCE The Aspartame Resource Center
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. Smoking a greater risk than HIV? Yes say health experts!!!!
2. Roche offers HIV drug expertise to poor nations
3. Good carb, bad carb? Experts debate.
4. Serevent, to be examined by experts due to deaths associated with its use
5. Spread Of Rocky Mountain Spotted Fever Is A Probability, Say Experts
6. Experts Recommend Preventive Measures For Avian Flu To Begin From Farms
7. Experts Insist That Neonatal Herpes Be Reported Regularly
8. Experts State Strategies To Increase Good Cholesterol
9. Speed up bird flu vaccine, Bush tells experts
10. Tennis elbow not new among cricketers, say experts
11. Weight-Loss Medication Evaluated By Nutrition Expert
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Daniel K. Spiegelman Elected to Board of Directors of Omeros 2Shanghai ChemPartner Is Pleased to be Part of Agios' Groundbreaking Cancer Research 2Finally a Health Care Option for Small Businesses 50925 1Finally a Health Care Option for Small Businesses 50925 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 12009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 22009 3A Immunotec announces important clinical research initiative 3A New study to be launched with the goal of improving the quality of the aging pro 12920 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 1Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 2Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 3Detroit Medical Center to Partner With my1HIE 28R 29 and Link With United Physicians and Olympia Physician Groups 50922 4
Other Medicine Technology:Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 2Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 3Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 4Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 5Freezing Kidney Cancer: Hot Treatment Should Be New Gold Standard for Destroying Small Tumors 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 2Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 3Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 4Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 5Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 6Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 7Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 8Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 9Human Genome Sciences Announces Positive Results in Second of Two Phase 3 Trials of Albuferon(R) in Chronic Hepatitis C 10